Technology ID
TAB-4863
Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections
E-Numbers
E-043-2011-0
Lead Inventor
Sullivan, Nancy
Lead IC
NIAID
Co-Inventors
Nabel, Gary
Asiedu, Clement
Cheng, Cheng
Pau, Maria
Goudsmit, Jaap
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Research Products
Research Equipment
Plasmids/Vectors
Animal Models
This technology presents a sophisticated two-step vaccination approach designed to provide comprehensive protection against filovirus infections, including Ebola and Marburg viruses. It involves administering a prime-boost vaccine sequence, employing replication-defective adenoviral serotype 26 (Ad26) as the priming agent and replication-defective adenoviral serotype 35 (Ad35) as the boosting agent. Both vectors are engineered to express the crucial filovirus envelope glycoprotein (GP), encompassing various strains of Ebolavirus (EBOV) and Marburg (MAR). The primary application of this technology is for preventative vaccination, offering significant potential in the fight against filovirus outbreaks and their devastating consequences.
Commercial Applications
This technology offers versatile applications. It can serve as a potent preventive vaccine against Ebola and Marburg viruses, safeguarding at-risk populations and healthcare workers during outbreaks. Its adaptability to diverse filovirus strains enhances its effectiveness in countering evolving viral threats. Furthermore, it holds potential for therapeutic use in treating individuals already infected with filoviruses, contributing significantly to public health efforts worldwide.
Competitive Advantages
This innovative technology offers a two-step prime-boost vaccination strategy using Ad26 and Ad35 vectors expressing various filovirus GP strains. This approach provides comprehensive immunity against different filovirus strains and adaptability to emerging variants. It has potential applications in both prevention and treatment, promising significant advancements in the fight against filovirus infections.
Licensing Contact: